GlassScriptPhysician profile
Vinni Juneja
NPI 1639223522
$35,812.21
in general payments reported to CMS, 2019-2025
84 companies · $5,678 in 2025
The $5,678 reported for 2025 was more than what 83% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,307 · 2020: $3,095 · 2021: $2,108 · 2022: $3,411 · 2023: $8,912 · 2024: $6,301 · 2025: $5,678.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Consulting Fee: $7,135 · Long Term Medical Supply Or Device Loan: $1,097 · Travel and Lodging: $283 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,276.88 |
| Consulting Fee | $7,135.00 |
| Long Term Medical Supply Or Device Loan | $1,096.70 |
| Travel and Lodging | $282.52 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $6,046.74 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Seagen INC. | $5,320.43 | 2019-2023 | Adcetris, Tivdak, Tukysa |
| Pfizer INC. | $2,883.85 | 2019-2025 | |
| Janssen Biotech, INC. | $2,611.12 | 2019-2025 | Tecvayli, Talvey, Darzalex |
| Novartis Pharmaceuticals Corporation | $2,296.79 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,798.18 | 2020-2025 | Fruzaqla, Iclusig |
| Abbvie INC. | $961.31 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $949.63 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Astrazeneca Pharmaceuticals LP | $919.25 | 2020-2025 | Imfinzi, Calquence, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $764.86 | 2020-2025 | Opdivo, Eliquis |
| Eisai INC. | $646.78 | 2019-2025 | |
| Incyte Corporation | $521.43 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Amgen INC. | $520.35 | 2019-2025 | Blincyto, Kyprolis, Uplizna |
| Glaxosmithkline, LLC. | $513.82 | 2020-2025 | Zejula, Jemperli, Ojjaara |
| Daiichi Sankyo INC. | $480.86 | 2022-2025 | Enhertu, Injectafer, Datroway |
Show all 83 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $446.72 | 2020-2025 | |
| Aveo Pharmaceuticals, INC. | $391.25 | 2021-2025 | Fotivda |
| Genentech USA, INC. | $379.78 | 2020-2025 | Venclexta, Polivy, Lunsumio |
| Pharmaessentia USA Corporation | $333.55 | 2022-2025 | Besremi |
| Lilly USA, LLC | $316.87 | 2020-2025 | Verzenio, Jaypirca, Retevmo |
| Dendreon Pharmaceuticals LLC | $289.05 | 2021-2025 | Provenge |
| Regeneron Healthcare Solutions, INC. | $283.64 | 2022-2025 | Libtayo |
| Astellas Pharma US INC | $276.27 | 2022-2025 | Padcev, Cresemba, Xospata |
| Array Biopharma INC | $268.58 | 2019-2025 | Braftovi, Mektovi, Lorbrena |
| Bayer Healthcare Pharmaceuticals INC. | $262.04 | 2021-2025 | |
| Rigel Pharmaceuticals, INC. | $259.38 | 2020-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Kite Pharma, INC. | $258.53 | 2019-2025 | Yescarta |
| Puma Biotechnology, INC. | $252.53 | 2021-2025 | Nerlynx |
| Beigene USA, INC. | $252.49 | 2022-2024 | Brukinsa |
| Taiho Oncology, INC. | $241.15 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $226.32 | 2019-2024 | |
| Pharmacyclics LLC, An Abbvie Company | $199.63 | 2020-2023 | Imbruvica |
| Alexion Pharmaceuticals, INC. | $198.75 | 2022-2025 | Ultomiris |
| Exelixis INC. | $187.68 | 2021-2025 | Cabometyx |
| Tersera Therapeutics LLC | $186.94 | 2022-2025 | Xermelo, Zoladex |
| Global Blood Therapeutics, INC. | $180.70 | 2020-2022 | |
| Sobi, INC | $164.60 | 2023-2025 | |
| Horizon Therapeutics Plc | $163.69 | 2023 | Uplizna, Tepezza |
| Mirati Therapeutics, INC. | $162.63 | 2023-2024 | Krazati |
| Adc Therapeutics America, INC. | $147.37 | 2021-2025 | |
| Pharmacosmos Therapeutics INC. | $132.58 | 2020-2024 | Monoferric |
| Agios Pharmaceuticals, INC. | $114.49 | 2024-2025 | Pyrukynd |
| Janssen Pharmaceuticals, INC | $112.30 | 2021-2025 | Erleada, Xarelto |
| Morphosys, US INC. | $110.82 | 2021-2023 | Monjuvi |
| Ipsen Biopharmaceuticals, INC | $110.49 | 2020-2024 | Onivyde, Somatuline Depot |
| Emd Serono, INC. | $91.71 | 2020-2025 | |
| Gilead Sciences, INC. | $88.96 | 2021-2025 | Trodelvy |
| Secura Bio, INC. | $81.27 | 2020-2021 | |
| Tactile Systems Technology INC | $74.53 | 2021-2025 | Nimbl, Flexitouch Plus |
| Adaptive Biotechnologies Corporation | $73.75 | 2022-2024 | Clonoseq |
| Servier Pharmaceuticals LLC | $69.43 | 2024-2025 | |
| Beone Medicines USA, INC. | $69.33 | 2025 | Brukinsa, Tevimbra |
| Genmab U.S., INC. | $68.77 | 2025 | Epkinly |
| Eusa Pharma (US) LLC | $63.55 | 2020-2022 | |
| Spectrum Pharmaceuticals INC. | $57.90 | 2023-2025 | Rolvedon |
| Karyopharm Therapeutics INC. | $54.69 | 2020-2022 | |
| Immunogen, INC. | $53.50 | 2023 | Elahere |
| Acrotech Biopharma INC. | $53.08 | 2023-2025 | Beleodaq |
| Alnylam Pharmaceuticals INC. | $50.95 | 2020-2024 | Givlaari |
| Clovis Oncology, INC. | $49.61 | 2020-2021 | |
| Sumitomo Pharma America, INC. | $49.25 | 2023-2025 | Orgovyx |
| Myriad Genetic Laboratories, INC. | $46.44 | 2020-2023 | Precisetumor |
| G1 Therapeutics, INC. | $44.98 | 2022-2023 | Cosela |
| Blueprint Medicines Corporation | $43.86 | 2020-2024 | Ayvakit |
| Boston Scientific Corporation | $40.67 | 2024 | Therasphere Y90 Glass Microspheres 10 Gbq |
| Shield Therapeutics INC | $38.67 | 2024-2025 | |
| Syndax Pharmaceuticals, INC. | $32.86 | 2025 | |
| Legend Biotech USA INC. | $32.59 | 2025 | Carvykti |
| Recordati_rare_diseases_inc. | $32.27 | 2023-2024 | Sylvant |
| Sanofi-Aventis U.S. LLC | $31.06 | 2022 | |
| Deciphera Pharmaceuticals INC. | $27.67 | 2022-2025 | Qinlock, Tgct |
| Kyowa Kirin, INC. | $24.67 | 2023 | Poteligeo |
| Fennec Pharmaceuticals, INC. | $24.41 | 2025 | Fyarro |
| Invivyd INC | $23.64 | 2024 | Pemgarda |
| Abbott Laboratories | $22.91 | 2023 | Jeti Peripheral Catheter |
| Epizyme, INC. | $22.27 | 2021 | |
| Springworks Therapeutics, INC. | $20.78 | 2025 | Ogsiveo |
| Coherus Oncology, INC. | $19.58 | 2021 | |
| Foundation Medicine, INC. | $19.58 | 2020 | |
| Novocure INC. | $17.22 | 2020 | |
| Shire North American Group INC | $17.14 | 2019 | |
| Amag Pharmaceuticals, INC. | $16.78 | 2020 | |
| Stemline Therapeutics INC. | $15.66 | 2023 | Orserdu |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
Adcetris $6,031Tecvayli $1,875Talvey $1,759Kisqali $1,428Elrexfio $591Keytruda $552Darzalex $433Lenvima $363Opdivo $362Enhertu $327Zejula $322Jemperli $318Fotivda $304Venclexta $301Padcev $294Xtandi $284Besremi $267Talzenna $247Oxbryta $229Brukinsa $228Orgovyx $213Libtayo $211Provenge $206Lynparza $205Uplizna $196Jaypirca $181Verzenio $181Sarclisa $179Doptelet $165Braftovi $163Krazati $163Inlyta $160Lonsurf $159Inqovi $159Ibrance $157Nubeqa $148Pluvicto $147Ultomiris $146Tukysa $144Yescarta $141Reblozyl $141Bosulif $140Mektovi $136Rezlidhia $135Tavalisse $135Epkinly $130Retevmo $130Rybrevant $128Welireg $127Xofigo $125Cabometyx $124Imfinzi $116Pyrukynd $114Qulipta $114Imbruvica $114Jakafi $112Stivarga $103Carvykti $97.26Injectafer $96.85Monjuvi $93.30Calquence $93.02Erleada $91.52Fruzaqla $91.52Xermelo $90.87Lorbrena $90.82Tivdak $90.21Pomalyst $88.24Elahere $87.45Eliquis $82.70Keytruda Qlex $74.77Monoferric $73.73Lunsumio $71.58Polivy $71.58Pemazyre $68.53Fabhalta $68.25Blincyto $61.67Kyprolis $61.67Clonoseq $58.73Rolvedon $57.90Ojjaara $56.49Scemblix $56.09Trodelvy $53.50Beleodaq $53.08Vitrakvi $53.03Emrelis $52.91Lutathera $50.72Onivyde $50.30Columvi $49.28Gavreto $46.74Ayvakit $45.34Lumakras $44.26Piqray $42.15Vectibix $41.41Xgeva $41.41Nplate $41.41Therasphere Y90 Glass Microspheres 10 Gbq $40.67Wayrilz $39.15Voranigo $39.07Accrufer $38.67Nerlynx $38.03
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vinni Juneja listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.